Apr 19, 2021 | Anti-METH antibody, IXT-m200, General News
IXT-m200 produced significant changes in primary endpoint of methamphetamine pharmacokinetics, with favorable data for secondary endpoints and safety LITTLE ROCK, AR, USA, April 19, 2021 – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...
Oct 5, 2020 | Anti-METH antibody, IXT-m200, General News, Grants
“Meth-OD” trial will be first known clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, ARKANSAS, USA, October 5, 2020 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical...
Jan 10, 2020 | General News, METH in the news
The misuse of methamphetamine, a highly addictive stimulant remains an extremely serious problem in the United States. Overdose deaths from meth are on the rise, caused in part by dealers who mix it with dangerous synthetic opioid fentanyl. Source: Overview | National...
Dec 20, 2019 | General News, METH in the news
Source: A New Drug Scourge: Deaths Involving Meth Are Rising Fast – The New York Times
Aug 12, 2019 | Anti-METH antibody, IXT-m200, General News
InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing immunotherapies for substance abuse disorders, today announced the expansion of its international intellectual property estate with the allowance of a key patent in Japan. In July...
Jul 29, 2019 | Anti-METH antibody, IXT-m200, General News, METH in the news
IXT-m200 produced immediate, dose-dependent, time-dependent changes in primary endpoint parameters of methamphetamine AUC and Cmax LITTLE ROCK, AR, USA, July 29, 2019 — InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing...
Recent Comments